Ad is loading...
NTLA
Price
$13.97
Change
-$1.15 (-7.61%)
Updated
Nov 15 closing price
94 days until earnings call
RVNC
Price
$4.17
Change
-$0.14 (-3.25%)
Updated
Nov 15 closing price
107 days until earnings call
Ad is loading...

NTLA vs RVNC

Header iconNTLA vs RVNC Comparison
Open Charts NTLA vs RVNCBanner chart's image
Intellia Therapeutics
Price$13.97
Change-$1.15 (-7.61%)
Volume$3.69M
CapitalizationN/A
Revance Therapeutics
Price$4.17
Change-$0.14 (-3.25%)
Volume$1.21M
CapitalizationN/A
NTLA vs RVNC Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RVNC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NTLA vs. RVNC commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a StrongSell and RVNC is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (NTLA: $13.97 vs. RVNC: $4.17)
Brand notoriety: NTLA and RVNC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 159% vs. RVNC: 38%
Market capitalization -- NTLA: $1.42B vs. RVNC: $437.44M
NTLA [@Biotechnology] is valued at $1.42B. RVNC’s [@Biotechnology] market capitalization is $437.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRVNC’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RVNC’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than RVNC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while RVNC’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • RVNC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than RVNC.

Price Growth

NTLA (@Biotechnology) experienced а -16.50% price change this week, while RVNC (@Biotechnology) price change was +12.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

RVNC is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.42B) has a higher market cap than RVNC($437M). RVNC (-52.560) and NTLA (-54.182) have similar YTD gains . RVNC has higher annual earnings (EBITDA): -274.04M vs. NTLA (-514.18M). NTLA has more cash in the bank: 691M vs. RVNC (232M). NTLA has less debt than RVNC: NTLA (106M) vs RVNC (492M). RVNC has higher revenues than NTLA: RVNC (251M) vs NTLA (46M).
NTLARVNCNTLA / RVNC
Capitalization1.42B437M326%
EBITDA-514.18M-274.04M188%
Gain YTD-54.182-52.560103%
P/E RatioN/AN/A-
Revenue46M251M18%
Total Cash691M232M298%
Total Debt106M492M22%
FUNDAMENTALS RATINGS
NTLA vs RVNC: Fundamental Ratings
NTLA
RVNC
OUTLOOK RATING
1..100
876
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
9364
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (33) in the Biotechnology industry is somewhat better than the same rating for RVNC (82) in the Pharmaceuticals Other industry. This means that NTLA’s stock grew somewhat faster than RVNC’s over the last 12 months.

NTLA's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as RVNC (100) in the Pharmaceuticals Other industry. This means that NTLA’s stock grew similarly to RVNC’s over the last 12 months.

NTLA's SMR Rating (95) in the Biotechnology industry is in the same range as RVNC (100) in the Pharmaceuticals Other industry. This means that NTLA’s stock grew similarly to RVNC’s over the last 12 months.

RVNC's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as NTLA (93) in the Biotechnology industry. This means that RVNC’s stock grew similarly to NTLA’s over the last 12 months.

RVNC's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NTLA (100) in the Biotechnology industry. This means that RVNC’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLARVNC
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 7 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RVNC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TOLIX16.770.15
+0.90%
DWS RREEF Global Infrastructure Inst
PREAX6.95N/A
N/A
PACE Global Real Estate Securities A
RDERX18.01-0.07
-0.39%
Columbia Large Cap Value Adv
MCBVX32.79-0.22
-0.67%
MFS Mid Cap Value B
DBOCX24.71-0.22
-0.88%
BNY Mellon Balanced Opportunity C

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-7.61%
VCYT - NTLA
69%
Closely correlated
-2.97%
EDIT - NTLA
68%
Closely correlated
-3.97%
BEAM - NTLA
67%
Closely correlated
-8.59%
CRSP - NTLA
64%
Loosely correlated
+0.85%
PRME - NTLA
58%
Loosely correlated
-6.95%
More

RVNC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RVNC has been loosely correlated with AXON. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if RVNC jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVNC
1D Price
Change %
RVNC100%
-3.25%
AXON - RVNC
39%
Loosely correlated
-0.86%
HRMY - RVNC
39%
Loosely correlated
+0.65%
ABCL - RVNC
37%
Loosely correlated
-3.99%
GOSS - RVNC
35%
Loosely correlated
-3.88%
NTLA - RVNC
34%
Loosely correlated
-7.61%
More